CClinicalTrials.gg
Not yet recruitingNCT07023133WLMFUpdated Jun 15, 2025

Impact of Weight Loss on Mitochondrial Function

An observational study in Weight Loss and Bariatric Surgery, sponsored by Towson University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-15.

Sponsored by Towson University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
15
Ages
18 Years and older
Sex
All
01

Study summary

Loss of body weight can elicit an adaptive decline in energy expenditure during rest and physical activity beyond what is expected based on the loss of metabolically active tissue, a phenomenon termed metabolic adaptation. The weight loss-induced decrease in energy expenditure (i.e., altered energy efficiency) can hinder continued weight loss and contributes to variation in weight loss success. The molecular mechanisms responsible for metabolic adaption include changes to sympathetic nervous system activity, decreases in leptin and thyroid hormones, and increases in skeletal muscle mitochondrial efficiency and capacity, though the dominant mechanism for metabolic adaptation is unclear. We have recently shown, using near-infrared spectroscopy (NIRS) technology, that we can non-invasively assess skeletal muscle mitochondrial efficiency (i.e., oxygen consumption rate) and capacity. The purpose of this study is to evaluate the association between skeletal muscle mitochondrial efficiency and capacity after weight loss with metabolic adaption and weight loss variability. To accomplish this aim, we will recruit individuals with obesity who have elected for bariatric surgery at local bariatric centers. We will assess their energy expenditure and mitochondrial efficiency and capacity before and after weight loss.

Read the detailed description

The procedures for this study involve two visit, one before bariatric surgery and one approximately 4 months after surgery, to our laboratory. The specific tests performed are listed below and are the same for each visit (each visit will take about 2 hours). Participants will be asked to arrive dressed in loose-fitting shorts that allow for assessments to be done on the lower leg.

Upon receipt of a signed consent form, a Demographics and Health History survey will be emailed to participants. Participants will be asked to complete the questionnaire in advance of their first in-person visit and will not be repeated at the second visit. The questionnaire will take \~10 minutes to complete and will be used to document any health conditions and medications.

Upon arrival for their in-person visit, we will measure the participant's seated blood pressure and heart rate as well as height and weight to calculate their body mass index (BMI). The following tests will then be performed:

  1. Body Composition measurement: A DEXA scan will be performed while the participant lays on their back. A separate risk acknowledgment form for the DXA scan will be provided. Female participants of childbearing age who believe they may be pregnant or are not sure, will be offered a free pregnancy test prior to the DEXA scan.
  2. Blood pressure (SphygmoCor) measurement: An automated pressure cuff will be placed on the participant's upper arm and inflated.
  3. Resting whole-body metabolism. This assessment measures the amount of energy the body needs at rest (i.e., resting metabolic rate) to maintain normal bodily function and will take approximately 20 minutes. Participants will be asked to lie down and rest quietly while their expired breath, collected via an open hood worn over the head, will be analyzed for oxygen and carbon dioxide content to assess their resting metabolic rate.
  4. Resting muscle metabolism: Muscle metabolism will be measured using near-infrared spectroscopy (NIRS), which is the typical use of the NIRS device. Specifically, a small mark will be placed on the center of the tibialis anterior (TA) muscle on the front of the dominant lower leg. An ultrasound machine will be used over the marked site on their muscle to capture an image and calculate the thickness of the TA muscle as well as the fat and skin layer over the muscle. Next, a small NIRS probe will be placed over the mark and secured into place with flexible wrap to minimize movement. There is no known risk associated with the NIRS device beyond potential irritation of the skin akin to the placement of any plastic device on the skin. NIRS measurements will be collected continuously through the duration of the test using blue-tooth. Small adhesive electrical stimulation pads will be placed on the TA muscle above and below the probe. A pneumatic blood pressure cuff will be placed around the thigh (upper leg) of their dominant leg just above the knee. The testing protocol will begin with resting measures that include 3 x 30s occlusions of the leg in which the blood pressure cuff will be inflated between 250-300mmHg. This will be followed by 30s stimulation of the muscle to mimic "exercise" to the TA muscle using electrical stimulation and then a series of short (6 x 5s) occlusions of the leg in which the blood pressure cuff will be again inflated between 250-300mmHg. The intensity of electrical stimulation is moderate and produces a tingling sensation and twitching of the muscle but is not painful. It provides a standardized muscle movement that mimics tapping of one's foot. This test will be repeated 4 times. When the repetitions are complete, the test will end with 5-minutes of blood pressure cuff occlusion and 3 minutes of data collection after the cuff is released.
  5. Walking metabolism measurement: Participant's customary walking speed and metabolic cost (i.e. rate of oxygen consumption) will be measured at the level of the whole-body and at the level of the muscle during a 5-minute walking test performed over a 20-meter course. Distance traveled during the 5 minutes will be used to calculate their walking speed. Whole-body metabolic cost will be calculated from the measurement of oxygen consumption and carbon dioxide production rates while walking using a COSMED indirect calorimeter device. Specifically, participants will walk while wearing a facemask (for collection of expired breath) connected to the COSMED device harnessed to their back. The COSMED and harness weigh less than 3 pounds. Muscle oxygen consumption rate (i.e., metabolic cost) while walking will be measured using the NIRS device previously placed on the TA muscle. A pneumatic blood pressure cuff will be placed around the thigh (upper leg) of their dominant leg just above the knee and inflated between 250-300 mmHg for 10 seconds at the end of the walking to allow for measurement of muscle oxygen consumption rate during the occlusion. Participants will also wear a polar hear rate monitor around their chest for measurement of heart rate while walking; heart rate will be recorded by the COSMED device via Bluetooth. These measures are painless and non-invasive. Given that participants will walk at their normal, customary gait speed, no screening for any medical conditions will be used for exclusion beyond those listed above. There is no risk beyond that risk associated with normal ambulation given the self-selected walking speed.
  6. Physical activity level. Objective daily physical activity data will be collected using a wrist-worn accelerometer. At the end of their visit, participants will be fitted with this watch-like device that is worn at the wrist, wear it for seven consecutive days.
02

Conditions studied

  • Weight Loss
  • Bariatric Surgery

Keywords

  • weight loss
  • bariatric surgery
03

In context

Body Weight

1,223 studies on the registry are indexed under Body Weight; 131 are open to participants now.

This study's planned enrollment of 15 is below the median of 140 across 238 observational studies indexed under Body Weight.

Browse Body Weight studies →

Lead sponsor

Towson University is the lead sponsor of 11 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Individuals with obesity that have self elected for bariatric surgery

Inclusion criteria

  • obesity (BMI>30 kg/m2); self elected for bariatric surgery

Exclusion criteria

Exclusion Criteria:

  • body mass > 350 pounds; presence of type 2 diabetes, thyroid disease, coronary heart disease, congenital heart disease, peripheral arterial disease; having a pacemaker; the use of a walking aid; the presence of an injury that would modify normal gait; and women who are currently pregnant or trying to become pregnant
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
15 participants (estimated)
Patient registry
No

Groups and cohorts

  • study cohort group

    The study cohort will be made up of individuals that have self selected for bariatric surgery.

    Behavioral: Weight loss

Interventions

  • BehavioralWeight loss

    All participants will have self selected for bariatric surgery and their weight loss and mitochondrial function will be measured in this study.

06

What researchers measure

Primary outcomes

  1. Weight loss

    The degree of weight loss after bariatric surgery

    Time frame: 4 months

  2. Mitochondrial function

    Degree of change in mitochondrial function as a result of weight loss

    Time frame: 4 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — The datasets generated during and/or analyzed during the current study will be available from the corresponding author on reasonable request.

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07023133
Lead sponsor
Towson University
Collaborators
Johns Hopkins University
Responsible party
Nicolas D. Knuth (Associate Professor, Towson University) — Principal investigator
First posted
Jun 15, 2025
Start date
Jul 28, 2025 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jun 15, 2025

Study contacts

Nicolas D Knuth, Doctor of Philosophy
Contact
nknuth@towson.edu
410-704-6247

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion